Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?

15Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Effects of pravastatin, simvastatin, atorvastatin, fluvastatin and cerivastatin on myocardial contractile dysfunction during reperfusion after brief ischemia were examined in dogs. Pretreatment of the dog with lipophilic HMG-CoA reductase inhibitors for 3 weeks, simvastatin (2 mg/kg/day), atorvastatin (2 mg/kg/day), fluvastatin (4 mg/kg/day), and cerivastatin (40 μg/kg/day) worsened recovery of myocardial contraction during reperfusion after brief ischemia in association with reduced myocardial ATP level. A hydrophilic HMG-CoA reductase inhibitor, pravastatin (2 and 4 mg/kg/day), did not affect the recovery of myocardial contractile function and ATP level during reperfusion following ischemia. The lipophilic inhibitors may enter the myocardial cell, inhibit ubiquinone biosynthesis, and depress ATP generation in mitochondria, leading to worsening of the myocardial stunning after reperfusion subsequent to ischemia.

Cite

CITATION STYLE

APA

Ichihara, K., Satoh, K., Yamamoto, A., & Hoshi, K. (1999). Are all HMG-CoA reductase inhibitors protective against ischemic heart disease? Folia Pharmacologica Japonica, 114(SUPPL. 1), 142–149. https://doi.org/10.1254/fpj.114.supplement_142

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free